Angiotensin II Receptor inhibition with candesartan to prevent trastuzumab-related cardiotoxic effects in patients with early breast cancer a randomized clinical trial

JAMA Oncology

Volumn 2, Issue 8, 2016, Pages 1030-1037

  Boekhout, Annelies H ^a,b   Gietema, Jourik A ^a   Kerklaan, Bojana Milojkovic ^a   VanWerkhoven, Erik D ^c   Altena, Renske ^a   Honkoop, Aafke ^d   Los, Maartje ^e   Smit, Willem M ^f   Nieboer, Peter ^g   Smorenburg, Carolien H ^h   Caroline, Mandigers P W ⁱ   Van DerWouw, Agnes J ^j   Kessels, Lonneke ^k   Van Der Velden, Annette W G ^l   Ottevanger, Petronella B ^m   Smilde, Tineke ⁿ   De Boer, Jaap ^b   Van Veldhuisen, Dirk J ^b   Kema, Ido P ^a   De Vries, Elisabeth G E ^b   Schellens, Jan H M ^o   more..

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c ISALA HOSPITAL   (Netherlands)

^d ST ANTONIUS HOSPITAL   (Netherlands)

^e MEDISCH SPECTRUM TWENTE   (Netherlands)

^f Wilhelmina Ziekenhuis   (Netherlands)

^g Location Alkmaar   (Netherlands)

^h CANISIUS WILHELMINA HOSPITAL   (Netherlands)

ⁱ VIECURI MEDICAL CENTER   (Netherlands)

^j DEVENTER HOSPITAL   (Netherlands)

^k MARTINI HOSPITAL   (Netherlands)

^l RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^m JEROEN BOSCH HOSPITAL   (Netherlands)

ⁿ De Tjongerschans Hospital   (Netherlands)

^o UTRECHT UNIVERSITY   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTINEOPLASTIC AGENT; BENZIMIDAZOLE DERIVATIVE; BRAIN NATRIURETIC PEPTIDE; CANDESARTAN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76); TETRAZOLE DERIVATIVE; TRASTUZUMAB; TROPONIN T;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; BLOOD; BREAST NEOPLASMS; CANCER STAGING; CARDIOTOXICITY; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DOUBLE BLIND PROCEDURE; ECHOCARDIOGRAPHY; FEMALE; GENETIC VARIATION; GENETICS; GENOTYPE; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; HUMAN; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; NETHERLANDS; ODDS RATIO; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANTINEOPLASTIC AGENTS; BENZIMIDAZOLES; BREAST NEOPLASMS; CARDIOTOXICITY; CHEMOTHERAPY, ADJUVANT; DOUBLE-BLIND METHOD; ECHOCARDIOGRAPHY; FEMALE; GENETIC VARIATION; GENOTYPE; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NATRIURETIC PEPTIDE, BRAIN; NEOPLASM STAGING; NETHERLANDS; ODDS RATIO; PEPTIDE FRAGMENTS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, ERBB-2; STROKE VOLUME; TETRAZOLES; TRASTUZUMAB; TROPONIN T; VENTRICULAR FUNCTION, LEFT;

EID: 85016924639     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2016.1726     Document Type: Article

References (47)

1. Gianni L, Dafni U, Gelber RD, et al; Herceptin Adjuvant (HERA) Trial Study Team. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: A 4-year follow-up of a randomised controlled trial. Lancet Oncol. 2011;12(3):236-244.
2. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 formetastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11): 783-792.
3. Untch M, Fasching PA, Konecny GE, et al. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol. 2011;29(25):3351-3357.
4. Perez EA, Romond EH, Suman VJ, et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol. 2011;29(25):3366-3373.
5. Romond EH, Jeong JH, Rastogi P, et al. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2012;30(31):3792-3799.
6. Procter M, Suter TM, de Azambuja E, et al. Longer-Term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial. J Clin Oncol. 2010;28(21):3422-3428.
7. Russell SD, Blackwell KL, Lawrence J, et al. Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: A combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials. J Clin Oncol. 2010;28(21):3416-3421.
8. Pinder MC, Duan Z, Goodwin JS, Hortobagyi GN, Giordano SH. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol. 2007; 25(25):3808-3815.
9. ClarkeM, Collins R, Darby S, et al; Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials. Lancet. 2005;366(9503): 2087-2106.
10. Patt DA, Goodwin JS, Kuo YF, et al. Cardiac morbidity of adjuvant radiotherapy for breast cancer. J Clin Oncol. 2005;23(30):7475-7482.
11. de Azambuja E, Procter MJ, van Veldhuisen DJ, et al. Trastuzumab-Associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01). J Clin Oncol. 2014;32(20): 2159-2165.
12. Doughty RN, Whalley GA, Gamble G, MacMahon S, Sharpe N; Australia-New Zealand Heart Failure Research Collaborative Group. Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. J AmColl Cardiol. 1997;29(5):1060-1066.
13. McMurray JJ, Ostergren J, Swedberg K, et al; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: The CHARM-Added trial. Lancet. 2003;362(9386):767-771.
14. Kalay N, Basar E, Ozdogru I, et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol. 2006;48(11): 2258-2262.
15. Kaya MG, Ozkan M, Gunebakmaz O, et al. Protective effects of nebivolol against anthracycline-induced cardiomyopathy: A randomized control study. Int J Cardiol. 2013;167 (5):2306-2310.
16. Nakamae H, Tsumura K, Terada Y, et al. Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone. Cancer. 2005;104(11):2492-2498.
17. Cadeddu C, Piras A, Mantovani G, et al. Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment. Am Heart J. 2010;160(3):487.e1-487.e7.
18. Cardinale D, Colombo A, Torrisi R, et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol. 2010;28(25):3910-3916.
19. Perik PJ, Lub-De Hooge MN, Gietema JA, et al. Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positivemetastatic breast cancer. J Clin Oncol. 2006;24(15):2276-2282.
20. SandriMT, SalvaticiM, Cardinale D, et al. N-Terminal pro-B-Type natriuretic peptide after high-dose chemotherapy: A marker predictive of cardiac dysfunction? Clin Chem. 2005;51(8):1405-1410.
21. Brouwers FP, van Gilst WH, Damman K, et al. Clinical risk stratification optimizes value of biomarkers to predict new-onset heart failure in a community-based cohort. Circ Heart Fail. 2014;7(5): 723-731.
22. Beauclair S, Formento P, Fischel JL, et al. Role of the HER2 [Ile655Val] genetic polymorphism in tumorogenesis and in the risk of trastuzumab-related cardiotoxicity. Ann Oncol. 2007;18(8):1335-1341.
23. Lemieux J, Diorio C, CA, et al. Alcohol and HER2 polymorphisms as risk factor for cardiotoxicity in breast cancer treated with trastuzumab. Anticancer Res. 2013;33(6):2569-2576.
24. Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002;20(5):1215-1221.
25. Tan TC, Bouras S, Sawaya H, et al. Time trends of left ventricular ejection fraction andmyocardial deformation indices in a cohort of women with breast cancer treated with anthracyclines, taxanes, and trastuzumab. J AmSoc Echocardiogr. 2015;28 (5):509-514.
26. Lan KKG, Demets DL. Discrete sequential boundaries for clinical trials. Biometrika. 1983;70: 659-663.
27. Minelli C, Thompson JR, Abrams KR, Thakkinstian A, Attia J. The choice of a genetic model in themeta-Analysis of molecular association studies. Int J Epidemiol. 2005;34(6):1319-1328.
28. Jalowy A, Schulz R, Heusch G. AT1 receptor blockade in experimentalmyocardial ischemia/reperfusion. Basic Res Cardiol. 1998;93 (suppl 2):85-91.
29. Thmann PA, Kenedi P, Schmidt A, Harder S, Rietbrock N. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation. 1998;98(19):2037-2042.
30. Iqbal M, Dubey K, Anwer T, Ashish A, Pillai KK. Protective effects of telmisartan against acute doxorubicin-induced cardiotoxicity in rats. Pharmacol Rep. 2008;60(3):382-390.
31. Cardinale D, Colombo A, Bacchiani G, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015;131(22):1981-1988.
32. Altena R, Perik PJ, van Veldhuisen DJ, de Vries EG, Gietema JA. Cardiovascular toxicity caused by cancer treatment: strategies for early detection. Lancet Oncol. 2009;10(4):391-399.
33. Cao L, Cai G, Chang C, et al. Diastolic dysfunction occurs early in her2-positive breast cancer patients treated concurrently with radiation therapy and trastuzumab. Oncologist. 2015;20(6): 605-614.
34. Hare JL, Brown JK, Leano R, Jenkins C, Woodward N, Marwick TH. Use ofmyocardial deformation imaging to detect preclinical myocardial dysfunction before conventional measures in patients undergoing breast cancer treatment with trastuzumab. Am Heart J. 2009;158 (2):294-301.
35. Negishi K, Negishi T, Haluska BA, Hare JL, Plana JC, Marwick TH. Use of speckle strain to assess left ventricular responses to cardiotoxic chemotherapy and cardioprotection. Eur Heart J Cardiovasc Imaging. 2014;15(3):324-331.
36. Thavendiranathan P, Grant AD, Negishi T, Plana JC, Popović ZB, Marwick TH. Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: Application to patients undergoing cancer chemotherapy. J AmColl Cardiol. 2013;61(1):77-84.
37. Grover S, Leong DP, Chakrabarty A, et al. Left and right ventricular effects of anthracycline and trastuzumab chemotherapy: A prospective study using novel cardiac imaging and biochemical markers. Int J Cardiol. 2013;168(6):5465-5467.
38. Perez EA, Suman VJ, Davidson NE, et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol. 2008;26(8):1231-1238.
39. Goel S, Simes RJ, Beith JM. Exploratory analysis of cardiac biomarkers in women with normal cardiac function receiving trastuzumab for breast cancer. Asia Pac J Clin Oncol. 2011;7(3):276-280.
40. Onitilo AA, Engel JM, Stankowski RV, Liang H, Berg RL, Doi SA. High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: A pilot study. Breast Cancer Res Treat. 2012; 134(1):291-298.
41. Sawaya H, Sebag IA, Plana JC, et al. Early detection and prediction of cardiotoxicity in chemotherapy-Treated patients. Am J Cardiol. 2011; 107(9):1375-1380.
42. Ky B, PuttM, Sawaya H, et al. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. J Am Coll Cardiol. 2014;63(8):809-816.
43. Morris PG, Chen C, Steingart R, et al. Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib. Clin Cancer Res. 2011;17 (10):3490-3499.
44. Fallah-Rad N, Walker JR, Wassef A, et al. The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy. J Am Coll Cardiol. 2011;57(22):2263-2270.
45. Stanton SE, Ward MM, Christos P, et al. Pro1170 Ala polymorphism in HER2-neu is associated with risk of trastuzumab cardiotoxicity. BMC Cancer. 2015;15:267.
46. Mailliez A, Ploquin A, Servent V, Bonneterre J. Trastuzumab cardiac toxicity and her2 polymorphism: A case-control study [abstract P3-14-11]. Cancer Res. 2010;70.
47. Cresti N, Verrill M, PinkilgtonM, Boddy AV. Fcy-receptor IIa polymorphism and cardiotoxicity in patients with breast cancer treated with adjuvant trastuzumab [abstract 565]. J Clin Oncol. 2011;29.